Parametrica Management’s Acadia Pharmaceuticals ACAD Stock Holding History

Parametrica Management’s Portfolio ACAD Stock Details ACAD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-30,516	Closed	-$744K	–	75
2021 Q2	$744K	Buy	30,516 +6,174	+25%	+$139K	0.55%	43
2021 Q1	$627K	Buy	+24,342	New	+$1.07M	0.3%	63
2019 Q2	–	Sell	-8,158	Closed	-$219K	–	5
2019 Q1	$219K	Buy	+8,158	New	+$191K	0.46%	131
2017 Q1	–	Sell	-18,223	Closed	-$526K	–	270
2016 Q4	$526K	Buy	+18,223	New	+$482K	0.52%	61

Other funds holding ACAD

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Parametrica Management's ACAD Position: Q3 2021 in Review

Parametrica Management sold out of Acadia Pharmaceuticals (ACAD) in Q3 2021, closing a stake of 30,516 shares — an estimated $744K sold.

Parametrica Management first reported a position in ACAD in Q4 2016 and held it in 4 quarters. The position peaked at $744K in Q2 2021. 237 funds tracked by Wall St. Rank hold ACAD as of Q3 2021.

Parametrica Management reported no remaining Acadia Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
Parametrica Management sold 30,516 Acadia Pharmaceuticals shares in Q3 2021, an estimated $744K.
Parametrica Management first reported a position in Acadia Pharmaceuticals in Q4 2016 and held it in 4 quarters.
Parametrica Management's Acadia Pharmaceuticals position peaked at $744K in Q2 2021.
237 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q3 2021.

Based on Parametrica Management's 13F filing for Q3 2021, filed 12 Nov 2021.